Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfex in Autologous HSCT for Multiple Myeloma
NCT00941720Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in multiple myeloma (MM), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Relapse-free Survival at 6 months and Overall Survival at 6 months. Started Jun 2009; status: completed.
02
Drugs
busulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00941720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941720.